List of Studies ( Metabolite:GalCer 18:1;O2/16:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004162 | AN006907 | Targeted Lipid Profiling of Mouse Brains with GBA1 E326K Loss-of-Function | Brain | Mouse | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004162 | AN006907 | Targeted Lipid Profiling of Mouse Brains with GBA1 E326K Loss-of-Function | Brain | Mouse | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006718 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006718 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST001820 | AN002955 | WT neurons treated with APOE3/3 and APOE4/4 ACM | Neurons | Mouse | Alzheimers disease | Columbia University | LC-MS |
| ST000917 | AN001501 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000916 | AN001495 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000915 | AN001489 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000859 | AN001384 | Targeted Galactosyl Sphingolipid Concentration in Kallikrein 6 Mice after SCI | Spinal cord | Mouse | Spinal cord injury | Mayo Clinic | LC-MS |
| ST000852 | AN001376 | Targeting Myelin Galactosyl Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Spinal cord | Mouse | Spinal cord injury | Mayo Clinic | LC-MS |
| ST000797 | AN001268 | Targeted Galactosyl Sphingolipids Concentrations of Myelin to Enhance Recovery of Function after SCI | Spinal cord | Mouse | Spinal cord injury | Mayo Clinic | MALDI-MS |
| ST000608 | AN000929 | Comparing identified and statistically significant lipids and polar metabolites in 15-year old serum and dried blood spot samples for longitudinal studies | Blood | Human | Pacific Northwest National Laboratory | GC-MS/LC-MS | |
| ST000608 | AN000930 | Comparing identified and statistically significant lipids and polar metabolites in 15-year old serum and dried blood spot samples for longitudinal studies | Blood | Human | Pacific Northwest National Laboratory | GC-MS/LC-MS |
